WaveMan
WaveMan · Company
TXG · 10X Genomics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TXG 10x Genomics (TXG) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001770787
Quote by TradingView
Form 144 · 11
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
202
13F, latest reported quarter

What the filings say about TXG

Insiders, 180 days
-$14.8M net sold
6 sellers · 47% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$11.7M
11 notices

10x Genomics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, 10x Genomics, Inc. insiders sold a net $14.8M of stock across 413 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
SULIMAN SHEHNAAZ
Director
SELL
2026-09-24 SECtraded 2026-09-22
292
$22.8K
-14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 24, 2026.
  • The trade is 1.0% of the 29,223 shares held after it.
  • 4 other insiders sold within 30 days.
  • 202 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULIMAN SHEHNAAZ sold about $22.8K of TXG under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 202 funds added in the latest 13F quarter.
SULIMAN SHEHNAAZ
Director
SELL
2026-09-24 SECtraded 2026-09-22
614
$48.8K
-14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 24, 2026.
  • The trade is 2.1% of the 28,609 shares held after it.
  • 4 other insiders sold within 30 days.
  • 202 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULIMAN SHEHNAAZ sold about $48.8K of TXG under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 202 funds added in the latest 13F quarter.
SULIMAN SHEHNAAZ
Director
SELL
2026-09-24 SECtraded 2026-09-22
1,325
$107.1K
-14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 24, 2026.
  • The trade is 4.9% of the 27,284 shares held after it.
  • 4 other insiders sold within 30 days.
  • 202 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULIMAN SHEHNAAZ sold about $107.1K of TXG under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 202 funds added in the latest 13F quarter.
SULIMAN SHEHNAAZ
Director
SELL
2026-09-24 SECtraded 2026-09-22
2,270
$185.4K
-14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 24, 2026.
  • The trade is 9.1% of the 25,014 shares held after it.
  • 4 other insiders sold within 30 days.
  • 202 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULIMAN SHEHNAAZ sold about $185.4K of TXG under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 202 funds added in the latest 13F quarter.
SULIMAN SHEHNAAZ
Director
SELL
2026-09-24 SECtraded 2026-09-22
1,222
$100.5K
-14.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 24, 2026.
  • The trade is 5.1% of the 23,792 shares held after it.
  • 4 other insiders sold within 30 days.
  • 202 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SULIMAN SHEHNAAZ sold about $100.5K of TXG under a 10b5-1 plan on Sep 22, 2026; 4 other insiders sold within 30 days and 202 funds added in the latest 13F quarter.
413 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 408 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$14.8M over 180 days
-$12.2M over 90 days
below 91% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
202 funds bought in last quarter
more than 83% of Medical Devices
Revenue
+5.2% year over year
below 65% of Medical Devices
Margin
-6.8% net margin
more than 61% of Medical Devices
Buybacks
no share repurchases reported
Short interest
13.0% of the float short (float per yahoo 2026-10-26) · 4.5 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TXG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+495.1%12M
+0%+232%+465%+697%2025-102025-122026-022026-042026-062026-082026-10 2026-09-09 · Taich Adam sold $2.0M2026-08-24 · Saxonov Serge sold $1.2M2026-08-24 · Taich Adam sold $1.1M2026-08-11 · STUELPNAGEL JOHN R sold $978.9K2026-09-09 · Taich Adam sold $897.6K2026-08-24 · Hindson Benjamin J. sold $870.9K2026-09-22 · Saxonov Serge sold $810.1K2026-09-22 · Saxonov Serge sold $752.4K2026-05-22 · Saxonov Serge sold $444.2K2026-09-03 · STUELPNAGEL JOHN R sold $425.3K2026-09-03 · STUELPNAGEL JOHN R sold $423.2K2026-08-26 · Saxonov Serge sold $415.5K2026-09-03 · STUELPNAGEL JOHN R sold $386.5K2026-05-22 · Taich Adam sold $369.0K2026-06-22 · Saxonov Serge sold $346.9K2026-06-22 · Saxonov Serge sold $342.5K2026-03-02 · Saxonov Serge sold $324.0K2026-08-13 · Teichmann Sarah A. sold $302.4K2026-06-22 · Saxonov Serge sold $283.9K2026-05-22 · Hindson Benjamin J. sold $283.4K2026-05-26 · Saxonov Serge sold $264.8K2025-11-24 · Saxonov Serge sold $252.0K2026-09-22 · Saxonov Serge sold $230.6K2025-11-24 · Taich Adam sold $225.9K2026-08-26 · Saxonov Serge sold $220.6K2026-03-23 · Saxonov Serge sold $191.3K2026-09-22 · SULIMAN SHEHNAAZ sold $185.4K2026-02-23 · Saxonov Serge sold $179.0K2026-08-11 · STUELPNAGEL JOHN R sold $176.2K2026-06-16 · SULIMAN SHEHNAAZ sold $174.6K2026-02-23 · Taich Adam sold $166.6K2026-09-22 · Saxonov Serge sold $159.2K2025-11-24 · Hindson Benjamin J. sold $157.4K2026-02-25 · Teichmann Sarah A. sold $147.1K2026-02-23 · Hindson Benjamin J. sold $145.4K2026-08-14 · Teichmann Sarah A. sold $129.9K2026-04-14 · Saxonov Serge sold $122.8K2026-09-22 · SULIMAN SHEHNAAZ sold $107.1K2026-08-24 · SULIMAN SHEHNAAZ sold $105.3K2026-09-22 · SULIMAN SHEHNAAZ sold $100.5K2026-03-24 · Saxonov Serge sold $97.6K2026-09-22 · Saxonov Serge sold $78.2K2026-09-22 · Shehnaaz Suliman filed to sell $452.7K2026-09-09 · ADAM TAICH filed to sell $3.0M2026-09-03 · STUELPNAGEL JOHN R filed to sell $1.2M2026-08-26 · Serge Saxonov filed to sell $2.2M2026-08-24 · Hindson Benjamin J. filed to sell $870.8K2026-08-24 · Saxonov Serge filed to sell $1.2M2026-08-24 · Shehnaaz Suliman filed to sell $143.7K2026-08-24 · Taich Adam filed to sell $1.1M2026-08-14 · SARAH A POLONIUS-TEICHMANN filed to sell $129.9K2026-08-13 · SARAH A POLONIUS-TEICHMANN filed to sell $302.4K2026-08-11 · STUELPNAGEL JOHN R filed to sell $1.2M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TXG: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
17,629,266 sh
$675.9M
BlackRock, Inc.
10,804,070 sh
$414.2M
ARK Investment Management LLC
10,003,057 sh
$383.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,982,492 sh
$267.7M
Quantinno Capital Management LP
5,469,698 sh
$209.7M

Congress trades in TXG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TXG planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Shehnaaz Suliman
Filed 2026-09-22
$452.7K
ADAM TAICH
Filed 2026-09-09
$3.0M
STUELPNAGEL JOHN R
Filed 2026-09-03
$1.2M
Serge Saxonov
Filed 2026-08-26
$2.2M
Hindson Benjamin J.
Filed 2026-08-24
$870.8K

TXG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$146.3M position · as of 2026-07-31
9.4%
ARK Innovation ETF
$183.8M position · as of 2026-07-31
3.3%
Global X Genomics & Biotechnology ETF
$1.8M position · as of 2026-05-31
3.2%
American Beacon ARK Transformational Innovation Fund
$5.0M position · as of 2026-06-30
3.1%
Simplify Health Care ETF
$11.2M position · as of 2026-06-30
3.1%
Fidelity Disruptive Medicine ETF
$1.3M position · as of 2026-05-31
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Serge Saxonov
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.3M
$6.8M
$2.8M
-88%
+25%
2024
$7.9M
-$21.2M
$4.4M
-90%
-7%
2023
$8.3M
$17.3M
$3.4M
-60%
-6%
2022
$18.8M
-$14.3M
$9.4M
-74%
-10%
2021
$11.7M
$20.8M
$5.0M
+5%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $14.8M sold by insiders over 180 days, 202 funds added last quarter, $11.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGDXCMEWTMDXOMIRMDLUNG

TXG financials

Revenue growth
+5.2%
XBRL, annual
Net margin
-6.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$616.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-12.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$121.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2020-12-31 (66 months older than the period end) plus current 2020-12-31 (66 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-9.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-7.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-9.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$642.8M$610.8M$618.7M$516.4M
Gross profit$443.9M$414.5M$409.3M$396.0M
Operating income-$61.0M-$194.6M-$265.3M-$167.9M
Net income-$43.5M-$182.6M-$255.1M-$166.0M
EPS (diluted)-0.35-1.52-2.18-1.46
Operating cash flow$136.1M$6.7M-$15.2M-$33.6M
Cashn/a$344.1M$359.3M$219.7M
SEC XBRL, fiscal years, as known on 2026-10-27

TXG Stock Sonar score 6/7 axes

Find similar shapesCompare

TXG ranks highest on financial health (99th percentile) and institutional and government (83rd), and lowest on insider conviction (6th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
58
Inputs
  • Return on equity-9.4% · 59 pct, sector of 183
  • Return on assets-7.5% · 59 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-9.9% · 56 pct, sector of 188
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 159
  • Cash flow to debtno debt to cover
Growth
41
Inputs
  • Revenue growth, YoY+5.2% · 35 pct, sector of 219
  • Backlog growth, YoY+3.6% · 47 pct, sector of 37
Insider conviction
6
Inputs
  • Net Form 4 buying (codes P and S), 180d-$8.5M · 12 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
83
Inputs
  • Funds adding, latest quarter202 · 83 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+13.0% · 13 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+10.8% · 49 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TXG filings, in plain words

Are 10x Genomics insiders buying or selling TXG?

In the 180 days to 2026-10-27, 10x Genomics insiders were net sellers, a net $14.8M across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of TXG?

Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $11.7M of stock; the latest, by Shehnaaz Suliman, was filed 2026-09-22.

Read the full summary

In the 180 days to 2026-10-27, 10x Genomics insiders were net sellers of TXG, a net $14.8M across purchases and sales reported on Form 4 by 6 sellers. 47% of the 38 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $11.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies